Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma

This study adds a drug called naxitamab (an antibody that targets cancer cells) to the standard induction chemotherapy for children with high-risk neuroblastoma — a cancer of the nervous system that most commonly affects young children. The goal is to improve initial response rates. **You may be eligible if...** - Your child has been newly diagnosed with high-risk neuroblastoma (stage 3 or 4 per INSS criteria) - Your child meets specific age and biological risk criteria (such as MYCN amplification or specific tumor features) - Your child has not yet received treatment for this diagnosis **You may NOT be eligible if...** - Your child has already received treatment for neuroblastoma - Your child's cancer does not meet the high-risk criteria for this trial - Your child has serious health problems that would make treatment unsafe Talk to your doctor to see if this trial is right for you.